

WEST Search History

DATE: Monday, December 05, 2005

Hide?	Set Name	Query	Hit Count
<i>DB=USPT,USOC,EPAB,JPAB,DWPI; THES=ASSIGNEE; PLUR=YES; OP=ADJ</i>			
<input type="checkbox"/>	L21	(rheumatoid arthritis or sclerosis or lupus) same (psoriatic) same (IL adj 8)	34
<input type="checkbox"/>	L20	L18 and (anti\$.clm.) and (IL adj 8)	1
<input type="checkbox"/>	L19	L18 and (anti\$.clm.)	4
<input type="checkbox"/>	L18	L17 and TNF.clm.	14
<input type="checkbox"/>	L17	(rheumatoid arthritis or sclerosis or lupus) same (psoriatic).clm.	103
<input type="checkbox"/>	L16	rheumatoid arthritis same (psoriatic).clm.	97
<input type="checkbox"/>	L15	L13 and TNF .clm.	113
<input type="checkbox"/>	L14	L13 same TNF	11
<input type="checkbox"/>	L13	rheumatoid arthritis same (psoriatic or nodosa or spondylarthropathies or bowel or spondylitis or crohn\$.clm.	664
<input type="checkbox"/>	L12	rheumatoid arthritis same (psoriatic or nodosa or spondylarthropathies or bowel or spondylitis or crohn\$)	14123
<input type="checkbox"/>	L11	L7 and (anti\$.clm.)	10
<input type="checkbox"/>	L10	L7 and (antibod\$.clm.)	1
<input type="checkbox"/>	L9	L7 and (anntibod\$.clm.)	0
<input type="checkbox"/>	L8	L7 and (cd30 or cd30l or cd153)	0
<input type="checkbox"/>	L7	L6 and inflammation .clm.	74
<input type="checkbox"/>	L6	L5 and TNF .clm.	94
<input type="checkbox"/>	L5	rheumatoid arthritis same (psoriatic or nodosa or spondylarthropathies or bowel).clm.	488
<input type="checkbox"/>	L4	rheumatoid arthritis same (psoriatic or nodosa or spondylarthropathies or bowel)	10428
<i>DB=USPT; THES=ASSIGNEE; PLUR=YES; OP=ADJ</i>			
<input type="checkbox"/>	L3	L2.clm.	1
<input type="checkbox"/>	L2	L1 same (inflammation or arthritis or immuno\$)	28
<input type="checkbox"/>	L1	cd153 or cd30l	131

END OF SEARCH HISTORY

☐ 14. Document ID: US 6528050 B1

L21: Entry 14 of 34

File: USPT

Mar 4, 2003

DOCUMENT-IDENTIFIER: US 6528050 B1
TITLE: Growth factor homolog zvegfg3

Detailed Description Text (131):

Zvegfg3 antagonists are also of interest in the treatment of inflammatory disorders, such as rheumatoid arthritis and psoriasis. In rheumatoid arthritis, studies suggest that VEGF plays an important role in the formation of pannus, an extensively vascularized tissue that invades and destroys cartilage. Psoriatic lesions are hypervascular and overexpress the angiogenic polypeptide IL-8.

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	EMC	Draw D
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-----	--------

☐ 15. Document ID: US 6495668 B1

L21: Entry 15 of 34

File: USPT

Dec 17, 2002

DOCUMENT-IDENTIFIER: US 6495668 B1
TITLE: Growth factor homolog ZVEGF4

Detailed Description Text (135):

Zvegfg4 antagonists are also of interest in the treatment of inflammatory disorders, such as rheumatoid arthritis and psoriasis. In rheumatoid arthritis, studies suggest that VEGF plays an important role in the formation of pannus, an extensively vascularized tissue that invades and destroys cartilage. Psoriatic lesions are hypervascular and overexpress the angiogenic polypeptide IL-8.

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	EMC	Draw D
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-----	--------

☐ 16. Document ID: US 6432673 B1

L21: Entry 16 of 34

File: USPT

Aug 13, 2002

DOCUMENT-IDENTIFIER: US 6432673 B1
**** See image for Certificate of Correction ****
TITLE: Growth factor homolog ZVEGF3

Detailed Description Text (132):

Zvegfg3 antagonists are also of interest in the treatment of inflammatory disorders, such as rheumatoid arthritis and psoriasis. In rheumatoid arthritis, studies suggest that VEGF plays an important role in the formation of pannus, an extensively vascularized tissue that invades and destroys cartilage. Psoriatic lesions are hypervascular and overexpress the angiogenic polypeptide IL-8.

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	EMC	Draw D.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-----	---------

☐ 17. Document ID: US 6369068 B1

L21: Entry 17 of 34

File: USPT

Apr 9, 2002

DOCUMENT-IDENTIFIER: US 6369068 B1

TITLE: Amino substituted pyrimidine containing compounds

Brief Summary Text (80):

Another aspect of the present invention, therefore, is the treatment of a CSBP/RK/p38 kinase mediated disease, in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound as described herein. Suitable diseases, include those mentioned herein for IL-1, IL-6, IL-8 and TNF and more specifically those disease which are CSBP/RK/p38 kinase mediated diseases. These include, but are not limited to psoriatic arthritis, Reiter's syndrome, rheumatoid arthritis, gout, traumatic arthritis, rubella arthritis, acute synovitis, rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gouty arthritis and other arthritic condition, sepsis, septic shock, endotoxic shock, gram negative sepsis, toxic shock syndrome, asthma, adult respiratory distress syndrome, chronic pulmonary inflammatory disease silicosis, pulmonary sarcososis, Alzheimer's disease, stroke, neurotrauma, reperfusion injury, CNS injuries, such as neurotrauma and ischemia, including both open and closed head injuries), restenosis, such as occurs following coronary angioplasty, cardiac and renal reperfusion injury, thrombosis, glomerular nephritis, cerebral malaria, chronic pulmonary inflammatory disease, bone resorption diseases, osteoporosis, graft vs. host reaction, allograft rejections, diabetes, Crohn's disease, ulcerative colitis or any other anti-inflammatory bowel disease (IBD), psoriasis, eczema, contact dermatitis, psoriasis, pyresis, sunburn, conjunctivitis, multiple sclerosis, or muscle degeneration.

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	EMC	Draw D.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-----	---------

☐ 18. Document ID: US 5900235 A

L21: Entry 18 of 34

File: USPT

May 4, 1999

DOCUMENT-IDENTIFIER: US 5900235 A

TITLE: Interleukin-8 as an antiviral and antitumor agent

Brief Summary Text (16):

There is accumulating evidence in support that IL-8 plays an important role in the inflammatory process of many pathologies; indeed, IL-8 has been detected in inflammatory tissues or exudates such as in psoriatic scale extracts, in synovial fluid from patients with rheumatoid arthritis or gout, in pleural fluid from emphysema patients, and in bronchoalveolar lavages from patients with respiratory distress syndrome. Moreover, antiviral properties have recently been ascribed to the chemokines RANTES and MIP-1.alpha. and .beta., belonging to the C-C chemokine

subfamily, which were found to induce inhibition of HIV-1, HIV-2 and SIV replication in vitro

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	FOUO	Drawings
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 19. Document ID: WO 2005063766 A2

L21: Entry 19 of 34

File: DWPI

Jul 14, 2005

DERWENT-ACC-NO: 2005-591254

DERWENT-WEEK: 200560

COPYRIGHT 2005 DERWENT INFORMATION LTD

TITLE: New phenyl compounds are p-38 kinase inhibitors useful to treat, prevent or ameliorate symptoms of e.g. thrombocytopenia, Crohn's disease and psoriasis

Basic Abstract Text (32):

USE - (I) are useful to treat p38 kinase mediated disease. (I) are useful to treat, prevent or ameliorate one or more symptoms of a disease (disorders of the proliferation of blood vessels and mesangial cells, fibrotic disorders, metabolic disorders, nervous system disease, and cancer (e.g. breast, stomach, pancreas cancer), resistant to cytotoxic agents; disease associated with uncontrolled angiogenesis; and of oncologic disease, rheumatoid spondylitis, gouty arthritis and other arthritic conditions, endotoxic shock, gram negative sepsis, cerebral malaria, chronic pulmonary inflammatory disease, silicosis, pulmonary sarcoidosis, bone resorption diseases, reperfusion injury, graft versus host reaction, allograft rejections, fever, myalgias due to infection, AIDS, malignancy, keloid formation, scar tissue formation, ulcerative colitis or pyresis) modulated by TNF, where the disease or disorder is associated with a viral infection (influenza and herpes) that is veterinary virus infection caused by equine infectious anaemia virus, caprine arthritis virus, visna virus, maede virus or retro virus, inflammatory (acute pancreatitis, chronic pancreatitis, asthma, allergies, and adult respiratory distress syndrome), autoimmune (glomerulonephritis, rheumatoid arthritis, systemic lupus erythematosus, scleroderma, chronic thyroiditis, Graves' disease, autoimmune gastritis, insulin dependent diabetes mellitus (type I), autoimmune hemolytic anemia, autoimmune neutropenia, thrombocytopenia, atopic dermatitis, chronic active hepatitis, myasthenia gravis, multiple sclerosis, inflammatory bowel disease, ulcerative colitis, Crohn's disease, psoriasis and graft versus host disease), infectious (sepsis, septic shock and shigellosis), degenerative (acute Alzheimer's disease, Parkinson's disease, cerebral ischemia, and other neurodegenerative diseases) and viral (acute hepatitis infection (including hepatitis A, hepatitis B and hepatitis C), HIV infection and cytomegalovirus retinitis)); or disorder (destructive bone (osteoporosis, osteoarthritis and multiple myeloma-related bone disorder), proliferative (acute and chronic myelogenous leukemia, metastatic melanoma, Kaposi's sarcoma and multiple myeloma) and angiogenic) that is modulated or affected by cytokine (IL-1 (preferred), TNF, IL-6 or IL-8) activity modulated by p38 kinase (p38 alpha , p38 beta (both preferred), p38 gamma or p38 delta) or in which cytokine activity is implicated. (I) are useful to treat disease or disorder (stroke, endotoxemia, toxic shock syndrome, inflammatory reaction induced by endotoxin, tuberculosis, atherosclerosis, muscle degeneration, cachexia secondary to infection, psoriatic arthritis, Reiter's syndrome, gout, traumatic arthritis, rubella arthritis, acute synovitis and pancreatic beta-cell disease) modulated by cytokine IL-1. (I) are useful to treat disease or disorder (chronic obstructive pulmonary disease, systemic lupus erythematosus, Grave's disease, diabetes, diseases characterized by massive neutrophil infiltration, shigellosis, ocular

neovascularization, infantile haemangiomas, severe acute respiratory syndrome, ARC, ischemia in stroke heart attacks, organ hypoxia, vascular hyperplasia, cardiac hypertrophy, thrombin induced platelet aggregation and conditions associated with prostaglandin endoperoxidase synthase-2), (asthma, cardiac reperfusion injury, renal reperfusion injury, thrombosis and glomerulonephritis) modulated by cytokine IL-8. (I) are also useful to reduce the expression of inducible pro-inflammatory proteins; to treat, prevent or ameliorate one or more symptoms of diseases or disorders associated with inducible pro-inflammatory proteins; and to treat, prevent or ameliorate symptoms of a disease characterized by deregulation of the activity of a kinase protein (all claimed).

Full	Title	Citation	Front	Review	Classification	Data	Reference			Claims	PublC	Draw D
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-------	--------

☐ 20. Document ID: EP 1530587 A1, WO 2004016654 A1, AU 2003255832 A1

L21: Entry 20 of 34

File: DWPI

May 18, 2005

DERWENT-ACC-NO: 2004-238794

DERWENT-WEEK: 200533

COPYRIGHT 2005 DERWENT INFORMATION LTD

TITLE: New interleukin-8-like polypeptide useful in the diagnosis, prevention and treatment of diseases, e.g. reproductive disorders, tumors, Alzheimer's disease and chronic obstructive pulmonary disease

Basic Abstract Text (12):

USE - The inventive polypeptide as an IL-8 like chemokine protein is used in pharmaceutical composition for the diagnosis, prevention and treatment of diseases, e.g. reproductive disorders, including infertility, cell proliferative disorders, including neoplasm, melanoma, lung, colorectal, breast, pancreas, head and neck or other solid tumors; myeloproliferative disorders, such as leukemia, non-Hodgkin lymphoma, leukopenia, thrombocytopenia, angiogenesis disorder, Kaposi's sarcoma; autoimmune/inflammatory disorders, including allergy, inflammatory bowel disease, arthritis, psoriasis and respiratory tract inflammation, asthma, or organ transplant rejection; cardiovascular disorders, including hypertension, oedema, angina, atherosclerosis, thrombosis, sepsis, shock, reperfusion injury, or ischemia; neurological disorders including central nervous system disease, Alzheimer's disease, brain injury, amyotrophic lateral sclerosis, or pain; developmental disorders; metabolic disorders including diabetes mellitus, osteoporosis, or obesity, AIDS or renal disease; infections including viral infection, bacterial infection, fungal infection, parasitic infection, rheumatoid arthritis, psoriatic arthritis, osteoarthritis, systemic lupus erythematosus, systemic sclerosis, scleroderma, polymyositis, glomerulonephritis, fibrosis, lung fibrosis and inflammation, allergic or hypersensitivity diseases, dermatitis, chronic obstructive pulmonary disease, Crohn's disease, ulcerative colitis, multiple sclerosis, septic shock, HIV infection, transplant rejection, wound healing, metastasis, endometriosis, hepatitis, liver fibrosis, cancer, analgesia, or vascular inflammation related to atherosclerosis (all claimed).

Hit List

[First Hit](#)[Clear](#)[Generate Collection](#)[Print](#)[Fwd Refs](#)[Bkwd Refs](#)[Generate OACS](#)

Search Results - Record(s) 21 through 30 of 34 returned.

☐ 21. Document ID: JP 2005527611 W, WO 2003099011 A1, AU 2003240818 A1, EP 1513403 A1

L21: Entry 21 of 34

File: DWPI

Sep 15, 2005

DERWENT-ACC-NO: 2004-053124

DERWENT-WEEK: 200560

COPYRIGHT 2005 DERWENT INFORMATION LTD

TITLE: Use of cardiac glycoside in inhibiting secretion of interleukin-8 from a cell and in the treatment of disease e.g. cystic fibrosis, cardiopulmonary bypass surgery, and cardiopulmonary arrest

Basic Abstract Text (5):

USE - For inhibiting or reducing the secretion of interleukin-8 (IL-8) from a cell (e.g. CF lung epithelial cell) secreting elevated levels of IL-8. For treating disease conditions associated with high levels of IL-8 secretion in a human suffering from e.g. cystic fibrosis, cardiopulmonary bypass surgery, cardiopulmonary arrest, inflammatory bowel disease, lung disorders and lung conditions, traumatic brain injury, stroke, transplant graft rejection, Alzheimer's disease, Parkinson's disease, HIV, viral infection and fever resistant to cyclooxygenase inhibitors (all claimed), atherosclerosis, noneosinophilic asthma, asthma, non-specific airway hyperresponsiveness, chronic pulmonary obstructive disease, nosocomial pneumonia, cerebral reperfusion injury, endotoxemia-induced acute respiratory distress syndrome, diabetes, proliferative diabetic retinopathy, kidney transplant graft rejection, lung transplant graft rejection, pancreas transplant graft rejection, intestine transplant graft rejection, heart transplant graft rejection, bladder transplant graft rejection, multiple organ transplant graft rejection, AIDS, HIV-1 associated dementia, viral infections, infection with adenovirus, infection with human rhino virus, infection with influenza virus, infection with herpes virus, cancer, cyclooxygenase-resistant fever, psoriasis, rheumatoid arthritis, Sjogren's syndrome, Behcet's disease, psoriatic arthritis, glomerulonephritis, thermal injury (e.g. thermal injury by sunburn), acute pancreatitis, smoke inhalation, acid injury to the lung and reexpansion pulmonary edema.

Full	Title	Citation	Front	Review	Classification	Date	Reference				Claims	ICWC	Drawings
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--	--------	------	----------

☐ 22. Document ID: CN 1646138 A, WO 2003080071 A1, KR 2003094515 A, AU 2003215954 A1, KR 2004017613 A, KR 2004034220 A, EP 1490072 A1, JP 2005526789 W

L21: Entry 22 of 34

File: DWPI

Jul 27, 2005

DERWENT-ACC-NO: 2003-788240

DERWENT-WEEK: 200577

COPYRIGHT 2005 DERWENT INFORMATION LTD

TITLE: Use of an agonist ligand specific to G2A receptor to induce neutrophil apoptosis and inhibit interleukin-8 release for treating/preventing associated diseases i.e. inflammatory diseases and ischemia reperfusion injury

Basic Abstract Text (10):

USE - (I) is used to manufacture an agent for treating a disease or disorder associated with the suppression of neutrophil apoptosis or excessive release of IL-8, particularly inflammatory diseases (inflammatory bowel disease, peritonitis, osteomyelitis, cellulitis, meningitis, cerebritis, pancreatitis, trauma-inducing shock, bronchial asthma, allergic rhinitis, cystic fibrosis, cerebral apoplexy, acute bronchitis, chronic bronchitis, acute bronchiolitis, chronic bronchiolitis, osteoarthritis, gout, spinal arthropathy, ankylosing spondylitis, Reiter's syndrome, psoriatic arthropathy, enteropathic spondylitis, juvenile arthropathy, juvenile ankylosing spondylitis, reactive arthropathy, infectious arthritis, post-infectious arthritis, gonococcal arthritis, tuberculous arthritis, viral arthritis, fungal arthritis, syphilitic arthritis, Lyme disease, arthritis associated with 'vasculitis syndrome', polyarteritis nodosa, hypersensitivity vasculitis, Wegener's granulomatosis, polymyalgia rheumatica, giant cell arteritis, calcium crystal deposition arthropathy, pseudogout, non-joint rheumatism, bursitis, tenosynovitis, epicondylitis (tennis elbow), neuropathic joint disease, hemarthrosis, Henoch-Schonlein purpura, hypertrophic osteoarthritis, multicentric reticulohistiocytoma, scoliosis, hemochromatosis, hemoglobinopathy, hyperlipoproteinemia, hypogammaglobulinemia, familial Mediterranean fever, Gerhardt Diseases, systemic lupus erythematosus, relapsing fever, psoriasis, multiple sclerosis, sepsis, septic shock, acute respiratory distress syndrome, multiple organ dysfunction syndrome, chronic obstructive pulmonary disease, rheumatic arthritis, acute lung injury and bronchopulmonary dysplasia) and ischemia-reperfusion injury (all claimed).

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	EMC	Draw D
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-----	--------

☐ 23. Document ID: US 6962996 B2, WO 2002100405 A1, US 6552019 B1, US 20030203905 A1, EP 1414455 A1, US 6759535 B2, AU 2002320267 A1, US 20040254216 A1, JP 2005500284 W

L21: Entry 23 of 34

File: DWPI

Nov 8, 2005

DERWENT-ACC-NO: 2003-167374

DERWENT-WEEK: 200573

COPYRIGHT 2005 DERWENT INFORMATION LTD

TITLE: New isoquinoline compounds are p38 inhibitors useful in the treatment of e.g. inflammatory bowel disease

Basic Abstract Text (22):

USE - In the preparation or a composition for treatment of inflammatory diseases e.g. acute pancreatitis, chronic pancreatitis, asthma, allergies, adult respiratory distress syndrome, autoimmune disease e.g. glomerulonephritis, rheumatoid arthritis, systemic lupus erythematosus, scleroderma, chronic thyroiditis, Grave's disease, autoimmune gastritis, diabetes, autoimmune hemolytic anemia, autoimmune neutropenia, thrombocytopenia, atopic dermatitis, chronic active hepatitis, myasthenia gravis, multiple sclerosis, inflammatory bowel disease, ulcerative colitis, Crohn's disease, psoriasis and graft versus host disease; destructive bone

disease e.g. osteoarthritis, osteoporosis, multiple myeloma-related bone disease, proliferative disorders e.g. myelogenous leukemia, chronic myelogenous leukemia, metastatic melanoma, Kaposi's sarcoma, multiple myeloma, infectious disease e.g. sepsis, septic shock and Shigellosis; viral disease e.g. acute hepatitis infection, HIV infection and CMV retinitis; neurodegenerative disease e.g. Alzheimer's disease, Parkinson's disease, cerebral ischemia, neurodegenerative disease caused by traumatic injury; allergies; reperfusion/ischemia in stroke, myocardial ischemia, renal ischemia, heart attack; angiogenic disorders e.g. solid tumors, ocular neovascularization, infantile haemangioma; organ hypoxia, vascular hyperplasia, cardiac hypertrophy, thrombin-induced platelet aggregation or conditions associated with prostaglandin endoperoxidase synthase-2 e.g. edema, fever, analgesia and pain e.g. neuromuscular pain, headache, cancer pain, dental pain and arthritis pain in a patient (claimed); also for treating IL-1-mediated diseases e.g. endotoxemia, toxic shock syndrome, tuberculosis, atherosclerosis, muscle degeneration, cachexia, psoriatic arthritis, Reiter's syndrome, gout, traumatic arthritis, rubella arthritis, acute synovitis, pancreatic beta -cell disease; tumor-necrosis factor-mediated disease e.g. rheumatoid spondylitis, gouty arthritis, eczema, adult respiratory distresses syndrome, cerebral malaria, chronic pulmonary inflammatory disease, silicosis, pulmonary sarcoidosis, bone resorption diseases, ARC or malignancy, keloid formation, scar tissue formation, pyresis and viral infections; IL-8-mediated diseases e.g. thrombosis and glomerulonephritis.

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	EMC	Draw D
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-----	--------

☐ 24. Document ID: US 20040132694 A1, WO 200267919 A1, EP 1357909 A1, AU 2002256981 A1, JP 2004520412 W

L21: Entry 24 of 34

File: DWPI

Jul 8, 2004

DERWENT-ACC-NO: 2002-713355

DERWENT-WEEK: 200445

COPYRIGHT 2005 DERWENT INFORMATION LTD

TITLE: New amide squaramides are Interleukin-8 receptor antagonists useful for treating chemokine mediated diseases e.g. psoriasis

Basic Abstract Text (27):

USE - For treating chemokine mediated diseases in which the chemokine binds to an IL-8 alpha or beta receptor in a mammal e.g. psoriasis, atopic dermatitis, osteoarthritis, rheumatoid arthritis, asthma, chronic obstructive pulmonary disease, adult respiratory distress syndrome, inflammatory bowel disease, Crohn's disease, ulcerative colitis, stroke, septic shock, multiple sclerosis, endotoxic shock, gram negative sepsis, toxic shock syndrome, cardiac and renal reperfusion injury, glomerulonephritis, thrombosis, graft versus host reaction, Alzheimer's disease, allograft rejections, malaria, restenosis, angiogenesis, atherosclerosis, osteoporosis, gingivitis and undesired hematopoietic stem cells release and diseases caused by respiratory viruses, herpes viruses, and hepatitis viruses, meningitis, cystic fibrosis, pre-term labor, cough, pruritus, multi-organ dysfunction, trauma, strains, sprains, contusions, psoriatic arthritis, herpes, encephalitis, CNS vasculitis, traumatic brain injury, CNS tumors, subarachnoid hemorrhage, post surgical trauma, interstitial pneumonitis, hypersensitivity, crystal induced arthritis, acute and chronic pancreatitis, acute alcoholic hepatitis, necrotizing enterocolitis, chronic sinusitis, uveitis, polymyositis, vasculitis, acne, gastric and duodenal ulcers, celiac disease, esophagitis, glossitis, airflow obstruction, airway hyperresponsiveness, bronchiolitis obliterans organizing pneumonia, bronchiectasis, bronchiolitis, bronchiolitis

obliterans, chronic bronchitis, cor pulmonae, dyspnea, emphysema, hypercapnea, hyperinflation, hypoxemia, hyperoxia-induced inflammations, hypoxia, surgical lung volume reduction, pulmonary fibrosis, pulmonary hypertension, right ventricular hypertrophy, sarcoidosis, small airway disease, ventilation-perfusion mismatching, wheeze, colds and lupus (all claimed).

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	EMC	Draw D
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-----	--------

☐ 25. Document ID: JP 2004511445 W, WO 200224206 A1, AU 200187895 A, EP 1318816 A1, US 20030149009 A1, US 6677326 B2

L21: Entry 25 of 34

File: DWPI

Apr 15, 2004

DERWENT-ACC-NO: 2002-372010

DERWENT-WEEK: 200426

COPYRIGHT 2005 DERWENT INFORMATION LTD

TITLE: Formulation for treatment of e.g. asthma, inflammatory bowel disease, psoriasis and rheumatoid arthritis comprises prednisolone or another corticosteroid

Basic Abstract Text (5):

USE - For treating asthma, inflammatory bowel disease, psoriasis, psoriatic arthritis, polymyalgia rheumatica, chronic obstructive pulmonary disease, rheumatoid arthritis, other polyarthropathies (claimed); rheumatica, atopic dermatitis; and for treating disorders associated with the release of cytokines e.g. F) tumor necrosis factor (TNF) alpha , interleukin (IL)-1, IL-2, IL-6 and IL-8.

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	EMC	Draw D
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-----	--------

☐ 26. Document ID: IN 200201080 P3, WO 200172960 A2, AU 200149354 A, EP 1272175 A2, CZ 200203192 A3, SK 200201368 A3, US 20030216375 A1, HU 200302614 A2, US 6680317 B2, CN 1452483 A, MX 2002009355 A1, JP 2004508287 W, ZA 200207576 A, KR 2004014901 A, BR 200108867 A

L21: Entry 26 of 34

File: DWPI

Mar 4, 2005

DERWENT-ACC-NO: 2002-089571

DERWENT-WEEK: 200547

COPYRIGHT 2005 DERWENT INFORMATION LTD

TITLE: New sulfonamide substituted diphenyl thiourea derivatives are interleukin 8 receptor inhibitor used for treating e.g. inflammation, arthritis, stroke, shock, transplant rejection, hepatitis, pneumonia, trauma and hypertension

Basic Abstract Text (14):

USE - Used to treat a chemokine mediated disease where the chemokine binds to an IL-8 alpha or beta receptor in a mammal (claimed). (I) Are used to treat IL-8, GRO alpha , GRO beta , GRO gamma , NAP-2 and ENA-78 mediated diseases. (I) Are used to treat a chemokine mediated disease, particularly psoriasis, atopic dermatitis, osteoarthritis, rheumatoid arthritis, asthma, chronic obstructive pulmonary

disease, adult respiratory distress syndrome, inflammatory bowel disease, Crohn's disease, ulcerative colitis, stroke, septic shock, multiple sclerosis, endotoxic shock, gram negative sepsis, toxic shock syndrome, cardiac and renal reperfusion injury, glomerulonephritis, thrombosis, graft versus host reaction, Alzheimer's disease, allograft rejections, malaria, restenosis, angiogenesis, atherosclerosis, osteoporosis, gingivitis and undesired hematopoietic stem cells release and diseases caused by respiratory viruses, herpesviruses, and hepatitis virus, meningitis, cystic fibrosis, pre-term labor, cough, pruritus, multi-organ dysfunctions, trauma, strains, sprains, contusions, psoriatic arthritis, herpes, encephalitis, CNS vasculitis, traumatic brain injury, CNS tumors, subarachnoid hemorrhage, post surgical trauma, interstitial pneumonitis, hypersensitivity, crystal induced arthritis, acute and chronic pancreatitis, acute alcoholic hepatitis, necrotizing enterocolitis, chronic sinusitis, uveitis, polymyositis, vasculitis, acne, gastric and duodenal ulcers, celiac disease, esophagitis, glossitis, airflow obstruction, airway hyperresponsiveness, bronchiolitis obliterans organizing pneumonia, bronchiectasis, bronchiolitis, bronchiolitis obliterans, chronic bronchitis, cor pulmonae, dyspnea, emphysema, hypercapnea, hyperinflation, hypoxemia, hyperoxia-induced inflammations, hypoxia, surgical lung volume reduction, pulmonary fibrosis, pulmonary hypertension, right ventricular hypertrophy, sarcoidosis, small airway disease, ventilation-perfusion mismatching, wheeze, cold and lupus (claimed).

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	EMMC	Drawn Out
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	-----------

☐ 27. Document ID: ES 2241675 T3, WO 200138314 A1, AU 200117832 A, EP 1233951 A1, JP 2003514900 W, EP 1233951 B1, DE 60020595 E

L21: Entry 27 of 34

File: DWPI

Nov 1, 2005

DERWENT-ACC-NO: 2001-381287

DERWENT-WEEK: 200577

COPYRIGHT 2005 DERWENT INFORMATION LTD

TITLE: New 3,4-dihydro-(1H)quinazolin-2-one compounds CSB/RK/p38 kinase inhibitors useful for treating e.g. arthritic, sepsis, shock, stroke, inflammation, diabetes, graft rejection, neurodegenerative disease, tumors, asthma or viral infection

Basic Abstract Text (9) :

USE - (I) can be used for inhibiting cytokines and treating cytokine mediated disease (e.g. IL-1, IL-6, IL-8, TNF or COX-2). (I) can be used for treating a CSBP/RK/p38 kinase mediated disease in a mammal e.g. psoriatic arthritis, Reiter's syndrome, gout, traumatic arthritis, rubella arthritis and acute synovitis, rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gouty arthritis and other arthritic conditions, sepsis, septic shock, endotoxic shock, gram negative sepsis, toxic shock syndrome, cerebral malaria, meningitis, ischemic and hemorrhagic stroke, neurotrauma/open or closed head injury, asthma, adult respiratory distress syndrome, chronic pulmonary inflammatory disease, chronic obstructive pulmonary disease, silicosis, pulmonary sarcososis, bone resorption disease, osteoporosis, restensosis, cardiac, brain and renal reperefusion injury, thrombosis, glomerularnephritis, chronic renal failure, diabetes, diabetic retinopathy, macular degeneration, graft versus host reaction, allograft rejection, inflammatory bowel disease, Crohn's disease, ulcerative colitis, neurodegenerative disease, muscle degeneration, diabetic retinopathy, macular degeneration, tumor growth and metastasis, angiogenic disease, eczema, contact dermatitis, psoriasis, sunburn and conjunctivitis (claimed). They can also be used for treating the common cold or respiratory viral infection caused by human rhinovirus (HRV), other

enteroviruses, coronavirus, influenza virus, parainfluenza virus, respiratory syncytial virus, or adenovirus, where the respiratory viral infection exacerbates asthma, chronic bronchitis, chronic obstructive pulmonary disease, otitis media or sinusitis (claimed). They can also be used in smoke induced airway inflammation caused by inhalation of cigarette smoke, inhalation of smoke produced from a burning plant material, or inhalation of burning smoke from fossil fuels, for inflammation enhanced cough e.g. cough variant asthma or eosinophilic bronchitis (claimed). (I) can also be used for treating neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and multiples sclerosis, fever and myalgias due to infection, such as influenza, brain infections including encephalitis (including HIV-induced forms), cerebral malaria, meningitis, ischemic and hemorrhagic stroke, cachexia secondary to infection or malignancy, cachexia secondary to AIDS, ARC (AIDS related complex), keloid formation, scar tissue formation, pain and pyresis, gingivitis or periodontitis. (I) can also be used for treating infections by viruses such as HIV-1, HIV-2, HIV-3, cytomegalovirus (CMV), adenovirus and the Herpes group of viruses or viral infections in animals e.g. lentivirus infections e.g. equine infectious anemia virus, caprine arthritis virus, visna virus, or maedi virus or retrovirus infections e.g. feline immunodeficiency (FIV), bovine immunodeficiency virus, or canine immunodeficiency virus or other retroviral infections.

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	IMC	Draw D
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-----	--------

☐ 28. Document ID: WO 9828292 A1, JP 2002515891 W

L21: Entry 28 of 34

File: DWPI

Jul 2, 1998

DERWENT-ACC-NO: 1998-387653

DERWENT-WEEK: 200238

COPYRIGHT 2005 DERWENT INFORMATION LTD

TITLE: New carboxy-indole piperidine derivatives - are IL-1, IL-8 and TNF production and cytokine p38/MAP kinase inhibitors, useful for treating e.g. inflammatory diseases and viral infections

Basic Abstract Text (2):

USE - (I) and (II) are IL-1, IL-8 and TNF production and cytokine p38/MAP kinase inhibitors. They are useful as antiinflammatory agents. The compounds are useful for treating CSBP/RK/p38 kinase mediated disease in a mammal and for inhibiting the synthesis of prostaglandin endoperoxide synthase-2 (PGHS-2). CSBP/RK/p38 kinase mediated diseases are e.g. such as psoriatic arthritis, Reiter's syndrome, rheumatoid arthritis, gout, traumatic arthritis, rubella arthritis and acute synovitis, rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gouty arthritis and other arthritic condition, sepsis, septic shock, endotoxic shock, gram negative sepsis, toxic shock syndrome, Alzheimer's disease, stroke, neurotrauma, asthma, ARDS, cerebral malaria, chronic pulmonary inflammatory disease, silicosis, pulmonary sarcosis, bone resorption disease, osteoporosis, restenosis, cardiac and renal reperfusion injury, thrombosis, glomerulonephritis, diabetes, graft versus host reaction, allograft rejection, inflammatory bowel disease, Crohn's disease, ulcerative colitis, multiple sclerosis, muscle degeneration, eczema, contact dermatitis, psoriasis, sunburn or conjunctivitis, especially asthma, osteoporosis or arthritis. They are also used to treat or prevent oedema, fever, algaesia, neuromuscular pain, headache, cancer pain or arthritic pain. The compounds may also be used in veterinary medicine in the treatment of virus infection such as lentivirus infections, e.g. equine infectious anaemia virus, caprine arthritis virus, visna virus or maedi virus or retrovirus

infections eg feline immunodeficiency virus, bovine immunodeficiency virus and canine immunodeficiency virus. They are also capable of inhibiting proinflammatory proteins such as COX-2 and prostaglandin endoperoxide synthase 2, the selectivity for COX-2 sparing the ulcerogenicity of COX-1 inhibition.

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	RMIC	Draw D.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	---------

☐ 29. Document ID: WO 9807425 A1, US 6414150 B1, AU 9740813 A, ZA 9707497 A, EP 956018 A1, JP 2001500122 W

L21: Entry 29 of 34

File: DWPI

Feb 26, 1998

DERWENT-ACC-NO: 1998-168886

DERWENT-WEEK: 200248

COPYRIGHT 2005 DERWENT INFORMATION LTD

TITLE: New 4,5-di:substituted imidazole derivatives and their salts - used to treat cytokine-mediated diseases e.g. arthritis, Reiter's syndrome, sepsis, Alzheimer's disease, stroke, neurotrauma, asthma, etc.

Basic Abstract Text (2):

USE - (I) are used to treat and prevent cytokine-mediated disease, by inhibiting pro-inflammatory cytokines such as tumour necrosis factor (TNF), interleukin (IL)-1, IL-6 and IL-8 as well as inducible pro-inflammatory cytokines such as cyclooxygenase (COX)-2. (I) are used in the treatment of CSBP/RK/p38 kinase-mediated diseases including psoriatic arthritis, Reiter's syndrome, rheumatoid arthritis, gout, traumatic arthritis, rubella arthritis and acute synovitis, rheumatoid spondylitis, osteoarthritis, gouty arthritis, and other arthritic conditions, sepsis, septic shock, endotoxic shock, Gram-negative sepsis, toxic shock syndrome, Alzheimer's disease, stroke, neurotrauma, asthma, adult respiratory distress syndrome, cerebral malaria, chronic pulmonary inflammatory disease, silicosis, pulmonary sarcososis, bone resorption disease, osteoporosis, restenosis, cardiac and renal perfusion injury, thrombosis, glomerulonephritis, diabetes, graft-versus-host reaction, allograft rejection, inflammatory bowel disease, Crohn's disease, ulcerative colitis, multiple sclerosis, muscle degeneration, eczema, contact dermatitis, psoriasis, sunburn and conjunctivitis, in the treatment of chronic diseases characterised by excessive, undesired or inappropriate angiogenesis, diabetic nephropathy and other ocular neovascularisations, tumour growth and metastasis, atherosclerosis and arthritis (all claimed).

Equivalent Abstract Text (2):

USE - (I) are used to treat and prevent cytokine-mediated disease, by inhibiting pro-inflammatory cytokines such as tumour necrosis factor (TNF), interleukin (IL)-1, IL-6 and IL-8 as well as inducible pro-inflammatory cytokines such as cyclooxygenase (COX)-2. (I) are used in the treatment of CSBP/RK/p38 kinase-mediated diseases including psoriatic arthritis, Reiter's syndrome, rheumatoid arthritis, gout, traumatic arthritis, rubella arthritis and acute synovitis, rheumatoid spondylitis, osteoarthritis, gouty arthritis, and other arthritic conditions, sepsis, septic shock, endotoxic shock, Gram-negative sepsis, toxic shock syndrome, Alzheimer's disease, stroke, neurotrauma, asthma, adult respiratory distress syndrome, cerebral malaria, chronic pulmonary inflammatory disease, silicosis, pulmonary sarcososis, bone resorption disease, osteoporosis, restenosis, cardiac and renal perfusion injury, thrombosis, glomerulonephritis, diabetes, graft-versus-host reaction, allograft rejection, inflammatory bowel disease, Crohn's disease, ulcerative colitis, multiple sclerosis, muscle degeneration, eczema, contact dermatitis, psoriasis, sunburn and conjunctivitis, in the treatment

of chronic diseases characterised by excessive, undesired or inappropriate angiogenesis, diabetic nephropathy and other ocular neovascularisations, tumour growth and metastasis, atherosclerosis and arthritis (all claimed).

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	EMC	Draw D
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-----	--------

☐ 30. Document ID: US 5670527 A

L21: Entry 30 of 34

File: DWPI

Sep 23, 1997

DERWENT-ACC-NO: 1997-501780

DERWENT-WEEK: 200111

COPYRIGHT 2005 DERWENT INFORMATION LTD

TITLE: New 1, 4, 5-substituted imidazole derivatives - useful in treatment of diseases caused by unregulated cytokine production, e.g., asthma, arthritis, inflammatory bowel disease or viral infections

Basic Abstract Text (2):

USE - (I) are useful in treatment of disease states caused or exacerbated by excessive or unregulated cytokine production, especially disease states mediated by IL-1, IL-6, IL-8 or TNF. They are useful in treatment of pain, rheumatoid arthritis, rheumatoid spondylitis, chronic pulmonary inflammatory disease, pulmonary sarcososis, pyresis, thrombosis, cerebral malaria, sunburn, pancreatic beta cells, osteoporosis, sepsis, septic shock, endotoxic shock, gram negative sepsis, osteoarthritis, traumatic arthritis, rubella arthritis, stroke, endotoxaemia, toxic shock syndrome, inflammatory bowel disease, tuberculosis, atherosclerosis, muscle degeneration, multiple sclerosis, cachexia, bone resorption, psoriatic arthritis, Reiter's syndrome, gout, acute synovitis, diabetes, Alzheimer's disease, ARDS, silicosis, reperfusion injury, graft versus host disease, allograft rejection, fever, Crohn's disease, ulcerative colitis, viral infections (e.g. HIV), eczema, psoriasis, conjunctivitis, asthma or glomerulonephritis. Administration is, e.g., oral, topical, parenteral or by inhalation.

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	EMC	Draw D
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-----	--------

Clear	Generate Collection	Print	Fwd Refs	Bkwd Refs	Generate OACS
-------	---------------------	-------	----------	-----------	---------------

Terms	Documents
(rheumatoid arthritis or sclerosis or lupus) same (psoriatic) same (IL adj 8)	34

Display Format:

[Previous Page](#)

[Next Page](#)

[Go to Doc#](#)

Hit List

[First Hit](#)[Clear](#)[Generate Collection](#)[Print](#)[Fwd Refs](#)[Bkwd Refs](#)[Generate OACS](#)

Search Results - Record(s) 31 through 34 of 34 returned.

☐ 31. Document ID: US 5656644 A

L21: Entry 31 of 34

File: DWPI

Aug 12, 1997

DERWENT-ACC-NO: 1997-414639

DERWENT-WEEK: 200375

COPYRIGHT 2005 DERWENT INFORMATION LTD

TITLE: New 2,4-di:aryl- 5-pyridyl- imidazole derivatives - used as cytokine inhibitors, e.g. for treating inflammation, arthritis, viral infections or asthma

Basic Abstract Text (2):

USE - (I) are pro-inflammatory cytokine inhibitors, especially inhibitors of the production of IL-1, IL-6, IL-8 and TNF, and are used for treating cytokine-mediated diseases. IL-1 mediated diseases include rheumatoid arthritis, osteoarthritis, endotoxaemia, toxic shock syndrome, endotoxin-induced inflammatory reaction, inflammatory bowel disease, tuberculosis, atherosclerosis, muscle degeneration, multiple sclerosis, cachexia, bone resorption, psoriatic arthritis, Reiter's syndrome, gout, traumatic arthritis, rubella arthritis, acute synovitis, diabetes and Alzheimer's disease. TNF mediated diseases include rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gouty arthritis, sepsis, septic shock, Gram negative sepsis, toxic shock syndrome, ARDS, cerebral malaria, chronic pulmonary inflammatory disease, silicosis, pulmonary sarcoidosis, osteoporosis, reperfusion injury, graft-versus-host reaction, allograft rejection, fever and myalgia due to infection, cachexia (secondary to infection, malignancy or AIDS), AIDS, ARC, keloid or scar tissue formation, Crohn's disease, ulcerative colitis, pyresis and viral infections (e.g. due to HIV, cytomegalovirus, influenza virus, herpes viruses, adenoviruses and various veterinary viruses). IL-8 mediated diseases include psoriasis, inflammatory bowel disease, asthma, cardiac and renal reperfusion injury, ARDS, thrombosis and glomerulonephritis. (I) can also be used for treating or preventing cytokine-mediated topical disorders such as inflamed joints, eczema, psoriasis, sunburn, conjunctivitis, pyresis or pain.

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	EMC	Grand
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-----	-------

☐ 32. Document ID: MX 217011 B, WO 9725045 A1, AU 9715774 A, ZA 9700174 A, US 5756499 A, NO 9803189 A, US 5864036 A, EP 900083 A1, BR 9706973 A, CN 1213306 A, CZ 9802164 A3, US 5977103 A, HU 9902460 A2, NZ 327044 A, AU 715900 B, MX 9805631 A1, US 6046208 A, JP 2000503302 W, KR 99077164 A, TW 505637 A, EP 900083 B1, DE 69724246 E, ES 2205167 T3

L21: Entry 32 of 34

File: DWPI

Oct 20, 2003

DERWENT-ACC-NO: 1997-372599

DERWENT-WEEK: 200467

COPYRIGHT 2005 DERWENT INFORMATION LTD

TITLE: New substituted imidazole compounds which inhibit proinflammatory cytokine (s) - are useful in treatment of, e.g. rheumatoid arthritis, septic shock, cerebral malaria, silicosis, osteoporosis, allograft rejection or Crohn's disease

Equivalent Abstract Text (2):

USE - (I) are used to treat diseases mediated by cytokines such as interleukin-1 (IL-1), interleukin-6 (IL-6), interleukin-8 (IL-8), tumour necrosis factor (TNF), and/or cytokine specific binding protein (CSBP/RK/p38) kinase. The conditions include psoriatic arthritis, Reuter's syndrome, rheumatoid arthritis, gout, traumatic arthritis, rubella arthritis and acute and acute synovitis, rheumatoid spondylitis, osteoarthritis, gouty arthritis, and other arthritic conditions, sepsis, septic shock, endotoxic shock, gram negative sepsis, toxic shock syndrome, Alzheimer's disease, stroke, neurotrauma, asthma, adult respiratory distress syndrome, cerebral malaria, chronic pulmonary inflammatory disease, silicosis, pulmonary sarcososis, bone resorption disease, osteoporosis, restenosis, cardiac and renal reperfusion injury, thrombosis, glomerulonephritis, diabetes, graft vs. host reaction, allograft rejection, inflammatory bowel disease, Crohn's disease, ulcerative colitis, eczema, contact dermatitis, psoriasis, sunburn and conjunctivitis. (I) inhibit the synthesis of prostaglandin endoperoxide synthase-2 (PGHS-2) in the treatment or prevention of oedema, fever, algesia, neuromuscular pain, cancer pain or arthritic pain (all claimed).

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	EMC	Grant D.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-----	----------

☐ 33. Document ID: US 5593991 A

L21: Entry 33 of 34

File: DWPI

Jan 14, 1997

DERWENT-ACC-NO: 1997-191558

DERWENT-WEEK: 200111

COPYRIGHT 2005 DERWENT INFORMATION LTD

TITLE: New imidazole derivs. - useful in treatment of diseases caused by unregulated cytokine prodn., e.g. asthma, arthritis, inflammatory bowel disease or viral infections

Basic Abstract Text (2):

USE - (I) are useful in treatment of disease states caused or exacerbated by excessive or unregulated cytokine prodn., esp. disease states mediated by IL-1, IL-6, IL-8 or TNF. They are useful in treatment of, e.g. pain, rheumatoid arthritis, stroke, endotoxaemia, toxic shock syndrome, inflammatory bowel disease, tuberculosis, atherosclerosis, muscle degeneration, multiple sclerosis, cachexia, bone resorption, psoriatic arthritis, Reiter's syndrome, gout, acute synovitis, diabetes, Alzheimer's disease, ARDS, silicosis, reperfusion injury, graft versus host disease, allograft rejection, fever, Crohn's disease, ulcerative colitis, viral infections (e.g. HIV), eczema, psoriasis, conjunctivitis, asthma or glomerulonephritis. Admin. is, e.g., oral, topical, parenteral or by inhalation.

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	EMC	Grant D.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-----	----------

☐ 34. Document ID: ES 2242351 T3, WO 9314081 A1, AU 9335923 A, ZA 9300213 A, ES

2053401 A1, NO 9402618 A, EP 623126 A1, FI 9403319 A, CZ 9401688 A3, ES 2053401 B1, SK 9400835 A3, JP 07503017 W, CN 1083473 A, HU 69714 T, NZ 249301 A, AU 671271 B, BR 9305809 A, US 5686455 A, EP 943616 A1, CA 2314425 A1, CA 2368862 A1, JP 2002097189 A, MX 202879 B, JP 3298641 B2, CA 2127876 C, EP 623126 B1, DE 69333616 E, ES 2227517 T3, EP 943616 B1, DE 69333805 E, DE 69333616 T2

L21: Entry 34 of 34

File: DWPI

Nov 1, 2005

DERWENT-ACC-NO: 1993-243110

DERWENT-WEEK: 200577

COPYRIGHT 2005 DERWENT INFORMATION LTD

TITLE: New 1,2-di:subst.-4-aryl-5-hetero-aryl-imidazole derivs. - useful as cytokine, e.g. interleukin-1,-6 or -8 and tumournecrosis factor, inhibitors, for treating arthritis and inflammatory disease, etc.

Basic Abstract Text (3):

USE - (I) inhibit proinflammatory cytokines (e.g. interleukin-1 (IL-1-, IL-6, IL-8 and tumour necrosis factor (TNF) and so are useful for treating diseases caused by excessive or unregulated cytokine prodn. in cells (partic. monocytes and/or macrophages). When inhibiting IL-1 prodn. (I) can be used to treat rheumatoid arthritis, osteoarthritis, endotoxaemia and/or toxic shock syndrome, acute or chronic inflammatory disease (e.g. inflammatory bowel disease) tuberculosis atherosclerosis, muscle degeneration, multiple sclerosis, cachexia bone resorption, psoriatic arthritis, Reiters syndrom, gout traumatic arthritis, rubella arthritis and acute synovitis. IL-1 activity is also linked to diabetes, pancreatic beta cells and Alzheimers disease. When inhibiting TNF, (I) may be useful for treating (rheumatoid arthritis and rheumatoid sponylitis etc.

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	Publ	Grant D.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

[Clear](#)[Generate Collection](#)[Print](#)[Fwd Refs](#)[Bkwd Refs](#)[Generate OACS](#)

Terms	Documents
(rheumatoid arthritis or sclerosis or lupus) same (psoriatic) same (IL adj 8)	34

Display Format: [Change Format](#)[Previous Page](#)[Next Page](#)[Go to Doc#](#)